Transplantation-associated thrombotic microangiopathy: twenty-two years later
- 14 November 2002
- journal article
- review article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 30 (11) , 709-715
- https://doi.org/10.1038/sj.bmt.1703710
Abstract
A syndrome of microangiopathic hemolytic anemia, renal dysfunction and neurological abnormalities was first noted in bone marrow transplant recipients 22 years ago. Now known as transplantation-associated thrombotic microangiopathy (TA-TMA) to distinguish it from other thrombotic microangiopathies, this disorder responds poorly to conventional treatments for thrombotic thrombocytopenic purpura. In this review, we discuss the incidence and risk factors for TA-TMA and describe a pathophysiologic model of the disorder based on results obtained from laboratory models of the thrombotic microangiopathies. We conclude by suggesting possible approaches to the early diagnosis and treatment of TA-TMA based on this model that may warrant testing in future clinical trials.Keywords
This publication has 48 references indexed in Scilit:
- Defibrotide as a promising treatment for thrombotic thrombocytopenic purpura in patients undergoing bone marrow transplantationBone Marrow Transplantation, 2002
- De novo hemolytic uremic syndrome postrenal transplant after cytomegalovirus infectionAmerican Journal of Kidney Diseases, 1999
- Severe thrombotic microangiopathy: an infrequent complication of bone marrow transplantationBone Marrow Transplantation, 1999
- Effect of recombinant human erythropoietin on endothelial cell apoptosisKidney International, 1999
- Thrombotic microangiopathy following allogeneic bone marrow transplantation is associated with intensive graft-versus-host disease prophylaxisBone Marrow Transplantation, 1998
- Defibrotide Protects Endothelial Cells, but not L929 Tumour Cells, from Tumour Necrosis Factor-α-mediated CytotoxicityJournal of Pharmacy and Pharmacology, 1995
- Chemotherapy-induced hemolytic uremic syndrome: Description of a potential animal modelJournal of Medical Primatology, 1995
- Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor alpha during graft-versus-host disease.The Journal of Experimental Medicine, 1992
- Nephrotoxicity of Cyclosporin a after Allogeneic Marrow TransplantationNew England Journal of Medicine, 1981
- CYCLOSPORIN A TO PREVENT GRAFT-VERSUS-HOST DISEASE IN MAN AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATIONThe Lancet, 1980